DK0949245T3 - Fremgangsmåde til alkylering af hindrede sulfonamider - Google Patents

Fremgangsmåde til alkylering af hindrede sulfonamider

Info

Publication number
DK0949245T3
DK0949245T3 DK99302287T DK99302287T DK0949245T3 DK 0949245 T3 DK0949245 T3 DK 0949245T3 DK 99302287 T DK99302287 T DK 99302287T DK 99302287 T DK99302287 T DK 99302287T DK 0949245 T3 DK0949245 T3 DK 0949245T3
Authority
DK
Denmark
Prior art keywords
alkylation
sulfonamides
hindered
hindered sulfonamides
Prior art date
Application number
DK99302287T
Other languages
Danish (da)
English (en)
Inventor
Joel Michael Hawkins
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK0949245T3 publication Critical patent/DK0949245T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
DK99302287T 1998-04-10 1999-03-25 Fremgangsmåde til alkylering af hindrede sulfonamider DK0949245T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8131098P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
DK0949245T3 true DK0949245T3 (da) 2002-01-28

Family

ID=22163376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99302287T DK0949245T3 (da) 1998-04-10 1999-03-25 Fremgangsmåde til alkylering af hindrede sulfonamider

Country Status (47)

Country Link
US (2) US6229025B1 (OSRAM)
EP (2) EP0949245B1 (OSRAM)
JP (2) JP3479511B2 (OSRAM)
KR (2) KR100357660B1 (OSRAM)
CN (3) CN1234396A (OSRAM)
AP (1) AP1095A (OSRAM)
AR (1) AR017731A1 (OSRAM)
AT (2) ATE206392T1 (OSRAM)
AU (2) AU755004B2 (OSRAM)
BG (1) BG63665B1 (OSRAM)
BR (2) BR9910110A (OSRAM)
CA (2) CA2268684C (OSRAM)
CO (1) CO4810299A1 (OSRAM)
DE (2) DE69900321T2 (OSRAM)
DK (1) DK0949245T3 (OSRAM)
DZ (1) DZ2754A1 (OSRAM)
EA (1) EA002277B1 (OSRAM)
EG (1) EG21985A (OSRAM)
ES (2) ES2163316T3 (OSRAM)
GT (1) GT199900047A (OSRAM)
HN (1) HN1999000043A (OSRAM)
HR (1) HRP990106B1 (OSRAM)
HU (2) HUP9901043A1 (OSRAM)
ID (2) ID23244A (OSRAM)
IL (2) IL129168A (OSRAM)
IN (1) IN192485B (OSRAM)
IS (1) IS5018A (OSRAM)
MA (1) MA24833A1 (OSRAM)
NO (1) NO991675L (OSRAM)
NZ (1) NZ335105A (OSRAM)
OA (1) OA11030A (OSRAM)
PA (1) PA8469601A1 (OSRAM)
PE (1) PE20000417A1 (OSRAM)
PL (2) PL343530A1 (OSRAM)
PT (1) PT949245E (OSRAM)
RU (1) RU2197479C2 (OSRAM)
SA (1) SA99200089A (OSRAM)
SG (1) SG75167A1 (OSRAM)
SK (1) SK45399A3 (OSRAM)
TN (1) TNSN99054A1 (OSRAM)
TR (2) TR199900756A2 (OSRAM)
TW (1) TW520354B (OSRAM)
UA (1) UA57039C2 (OSRAM)
UY (1) UY25469A1 (OSRAM)
WO (1) WO1999052862A1 (OSRAM)
YU (1) YU18399A (OSRAM)
ZA (2) ZA992627B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1134207A1 (en) * 2000-03-15 2001-09-19 Pfizer Products Inc. Process for preparing resorcinol derivatives
EP1208092B1 (en) * 2000-04-07 2006-06-21 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
US6844373B2 (en) * 2002-05-28 2005-01-18 Alcatel Composition comprising fluorinated, radiation-curable dyes for surface energy control
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ITBO20050005U1 (it) * 2005-01-31 2006-08-01 Ali Spa Distributore di bevande ghiacciate e simili

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU523636A3 (ru) * 1973-06-18 1976-07-30 Стауффер Кемикал Компани (Фирма) Способ получени сульфоксидных или сульфоновых производных тиокарбаматов
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PL331895A1 (en) * 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
ID23668A (id) 1997-08-08 2000-05-11 Pfizer Prod Inc Turunan asam ariloksiarilsulfonilamino hidroksamat
ES2176913T3 (es) 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico

Also Published As

Publication number Publication date
UA57039C2 (uk) 2003-06-16
ATE206392T1 (de) 2001-10-15
ZA992627B (en) 2000-10-09
UY25469A1 (es) 1999-11-17
ATE284864T1 (de) 2005-01-15
BR9902219A (pt) 2000-04-11
HRP990106B1 (en) 2003-08-31
EP1068180B1 (en) 2004-12-15
TNSN99054A1 (fr) 2005-11-10
AU3552799A (en) 1999-11-01
CO4810299A1 (es) 1999-06-30
AU755004B2 (en) 2002-11-28
JP2002511447A (ja) 2002-04-16
IL129168A0 (en) 2000-02-17
CA2327498A1 (en) 1999-10-21
US6114568A (en) 2000-09-05
BG103320A (en) 2001-08-31
AU760213B2 (en) 2003-05-08
CN1296474A (zh) 2001-05-23
YU18399A (sh) 2002-11-15
NZ335105A (en) 2000-03-27
PT949245E (pt) 2002-02-28
DE69922638T2 (de) 2005-05-19
US6229025B1 (en) 2001-05-08
ID27208A (id) 2001-03-08
AU2369199A (en) 1999-10-21
EP1068180A1 (en) 2001-01-17
IS5018A (is) 1999-10-11
IL138778A0 (en) 2001-10-31
KR20010042567A (ko) 2001-05-25
HU9901043D0 (en) 1999-06-28
KR100377718B1 (ko) 2003-03-26
RU2197479C2 (ru) 2003-01-27
NO991675L (no) 1999-10-11
ID23244A (id) 2000-03-30
CN1288885A (zh) 2001-03-28
ZA200005370B (en) 2002-01-03
TR200002950T2 (tr) 2000-12-21
KR100357660B1 (ko) 2002-10-25
PL332451A1 (en) 1999-10-11
PA8469601A1 (es) 2000-09-29
DE69922638D1 (de) 2005-01-20
CA2327498C (en) 2006-01-31
MA24833A1 (fr) 1999-12-31
WO1999052862A1 (en) 1999-10-21
DZ2754A1 (fr) 2003-09-15
TR199900756A2 (xx) 1999-11-22
SK45399A3 (en) 2000-08-14
SA99200089A (ar) 2005-12-03
EA199900277A2 (ru) 1999-10-28
HRP990106A2 (en) 1999-12-31
SG75167A1 (en) 2000-09-19
CA2268684C (en) 2004-07-13
IL129168A (en) 2003-07-06
BG63665B1 (bg) 2002-08-30
CA2268684A1 (en) 1999-10-10
HUP0101465A3 (en) 2002-11-28
DE69900321T2 (de) 2002-07-11
DE69900321D1 (de) 2001-11-08
EP0949245A1 (en) 1999-10-13
BR9910110A (pt) 2001-10-09
HUP0101465A2 (hu) 2002-03-28
TW520354B (en) 2003-02-11
IN192485B (OSRAM) 2004-04-24
AR017731A1 (es) 2001-09-12
PL343530A1 (en) 2001-08-27
AP9901506A0 (en) 1999-06-30
OA11030A (en) 2002-02-07
NO991675D0 (no) 1999-04-09
EA002277B1 (ru) 2002-02-28
JP3540959B2 (ja) 2004-07-07
PE20000417A1 (es) 2000-05-24
KR19990082986A (ko) 1999-11-25
CN1234396A (zh) 1999-11-10
HUP9901043A1 (hu) 2000-08-28
EP0949245B1 (en) 2001-10-04
HN1999000043A (es) 1999-11-03
ES2234253T3 (es) 2005-06-16
AP1095A (en) 2002-08-26
JP2000026400A (ja) 2000-01-25
EA199900277A3 (ru) 2000-04-24
GT199900047A (es) 2000-09-15
ES2163316T3 (es) 2002-01-16
JP3479511B2 (ja) 2003-12-15
EG21985A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
DK0708114T3 (da) Fremgangsmåde til fremstilling af alkylerede galactomannaner
DK1527035T3 (da) Kontinuerlig fremgangsmåde til alkyleringen af carbonhydrider
DK1008577T4 (da) Fremgangsmåde til fremstilling af methanol
DK1123284T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1070694T3 (da) Fremgangsmåde til alkylering af isoparaffiner med olefiner
DK1772141T3 (da) Fremgangsmåde til gennemföring af krystallisation i fast tilstand
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1051194T3 (da) Fremgangsmåde til fremstilling af absorberbare mikropartikler
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
FI20030259L (fi) Menetelmä aromaattisten yhdisteiden alkyloimiseksi
DK1456154T3 (da) Fremgangsmåde til alkylering af benzen
DK1142990T3 (da) Fremgangsmåde til fremstilling af transglutaminase
DK0996642T3 (da) Fremgangsmåde til fremstilling af heparin
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
IT1299035B1 (it) Processo per la preparazione di composti aromatici monoalchilati
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1119635T3 (da) Ikke-homogene systemer til spaltning af enantiomerblandinger
DK0985733T3 (da) Fremgangsmåde til fremstilling af cyclodextrin
DK0973769T3 (da) Fremgangsmåde til fremstilling af eprosartan
NO991675L (no) Fremgangsmaate for alkylering av hindrede sulfonamider
DK0970073T3 (da) Fremgangsmåde til fremstilling af eprosartan
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
DK0981950T3 (da) Fremgangsm,åde til formering af phyllocactus
NO20005041D0 (no) FremgangsmÕte for Õ inhibere MRP1